Dosimetric Considerations for 177 Lu-DOTATATE Therapy in a Patient With Chronic Renal Failure Under Hemodialysis.

Abstract: This case report explores the use of 177 Lu-DOTATATE in a hemodialysis patient. For the first time, this study assesses the average dose received by the bone marrow, the primary organ at risk, using an original double estimation method through independently acquired imaging and biological samples counting data. Despite elevated doses, the absorbed doses to the bone marrow (0.662-0.740 Gy) were within safe limits. Radiation protection measurements for staff were also compliant. This work supports that effective early dialysis and systematic personalized dosimetry are crucial for hemodialysis patients undergoing 177 Lu-PRRT due to their variability (residual excretion, treatment history, etc).
Competing Interests: Conflicts of interest and sources of funding: none declared. Conflicts of interest and sources of funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)